Bruce A C Cree, MD, PhD, MAS - BTK Inhibition & Beyond: Novel Therapies in MS

Visit https://www.peervoice.com/EWH860 to view the entire programme with slides. After completing “Bruce A C Cree, MD, PhD, MAS - BTK Inhibition & Beyond: Novel Therapies in MS”, participants will be able to: Summarise the challenges in optimising outcomes for patients with multiple sclerosis (MS); Describe the mechanistic rationale for targeting Bruton tyrosine kinase (BTK) and CD40-CD40L in MS; Utilise efficacy and safety data regarding BTK inhibitors in evaluating treatment strategies for MS; and Evaluate the data from trials examining the safety and efficacy of novel investigational agents including anti-CD40L monoclonal antibodies (mAbs) in MS.